WO1992010999A1 - Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes - Google Patents

Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes Download PDF

Info

Publication number
WO1992010999A1
WO1992010999A1 PCT/US1991/009201 US9109201W WO9210999A1 WO 1992010999 A1 WO1992010999 A1 WO 1992010999A1 US 9109201 W US9109201 W US 9109201W WO 9210999 A1 WO9210999 A1 WO 9210999A1
Authority
WO
WIPO (PCT)
Prior art keywords
bleeding
powder
surgery
photograph
blood
Prior art date
Application number
PCT/US1991/009201
Other languages
French (fr)
Inventor
Leslie Binshyang Soong
Original Assignee
Leslie Binshyang Soong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leslie Binshyang Soong filed Critical Leslie Binshyang Soong
Priority to AU91034/91A priority Critical patent/AU662505B2/en
Priority to EP92901379A priority patent/EP0644754A4/en
Publication of WO1992010999A1 publication Critical patent/WO1992010999A1/en
Priority to NO1993930858A priority patent/NO930858D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof

Definitions

  • the substance powder 001 that can stop (stanch) bleeding in surgical, postsurgical, medical and dental uses or any bleeding due to any causes by topical administration or the substance powder 001 that has very potent hemostatic action can be administered topically to stop bleeding during surgery, after surgery, medicine by ingestion, dental surgery, extraction of teeth, and any injury or due to any causes for any normal and pathological persons.
  • Tattersal and Seville 1950 reported purpura in 60 out of 809 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and forearms. and on the backs of their hands, noth patients. and the controls were ascorbate deficient, as judged by ascorbic acid loading tests; skin biopsies from those with purpura showed degeneration of the collagen fibres of the dermis.
  • THIS invention pertains to the field of disorder of hemostasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboembolic disorders.
  • the blood coagulation mechanism of ascorbi c acid which was administered topically does not fall into either
  • the present methods available to stop bleeding in surgery are cautery, epinephrine injection, pressure and some fiber foam.
  • the cautery can cause tissue necrosis in
  • the epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly w el l for diffuse capillary bleeding and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency of the kinds of aforementioned patients.
  • the ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRNA in the regulation of col l agen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
  • Substance powder 001 represents ascorbic acid powder that is obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding when spraying it topically on the bleeding a rea for any
  • hemophilia blood needs 0.1568 g of ascorbic acid powder.
  • Sufficient substance powder 001 is particularly useful to help stop bleeding in the case of diffuse capillary oozing and mistakenly cut off artery or arteries that cannot be found during massive bleeding bleeding so as to save the patients' lives.
  • the present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, pressure and some fiber foam.
  • the cautery can cause tissue necrosis in some cases.
  • the epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capi l l ary oozing patients, while ascorbic acid powder does not cause any tissue necrosis and particularly works well for diffuse capillary bleeding and oozing and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients.
  • the ascorbic acid also facilitate wound healing ( Oral Surg.
  • the substance powder 001 is made by grinding the pure vitamin C tablets into powder.
  • the amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this vitamin C powder to coagulate 1 ml of human blood. This is the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this situation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows:
  • Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off.
  • Photograph # 1 massive bleeding when the femoral artery is cut off
  • Photogrph # 2 bleeding stops within one second when sufficient powder of interest was poured topically into
  • the amount of the powder needed is proportional to the amount of blood coming out of the vessel.
  • Photograph # 3 In the case of capillary bleeding
  • This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
  • the operation of stopping bleeding consists of combining the powder with press with gauze.
  • those that look black in color indicate the black blood coagulation ( Photograph # 14), while those that are white in color are those the powder does not get mixed up with the blood ( Photograph # 15).
  • Photograph # 16 At the end of the operation, most of black blood coagulation was wiped out with 4x4 gauze, and rinsed with Ringer's solution ( Photograph # 16 ). It took totally 5 minutes to stop the bleeding completely. The patient's conditions are especially well, better than without using this powder.
  • Photograph # 17 When the skin graft is removed from the hand,massive bleeding occurs ( Photograph # 17) . On applying sufficient powder to the bleeding area topically, it appears black coagulation within one second. Bleeding stops nt the same time ac the black coagulation forms. Those that appears white indicate the powder not yet mixed up with the blood. ( Photograph 4 18); those that appears more black area indicate the more powder mixed up with the blood (Photograph # 19), Suture going on ( Photograph # 20 ) Case 4. Age 70, female, paraanal abscess excision, bleeding when it is opened up ( Photograph # 21 ). When spraying the powder to the bleeding area, it stop bleeding by forming black blood coagulation immediately. Those that appears white are the powder that are not mixed up with the blood. ( Photograph # 212), Suture going on ( Photograph # 23 ).
  • Photograph # 24 On spraying the powder topically to the bleeding area, the black color is formed immediately because of the blood coagulation ( Photograph # 25 ) .
  • the white color is the powder instantly not mixed up with the blood yet. ( Photograph # 25 ), lastly, insert the long gauze into the anus. ( Photograph # 27 )
  • Photograph # 29 Wipe out the black coagulation in 10 seconds, stop bleeding still persisted ( Photograph # 30 )
  • blood requires 0.1568 g of powder to form black blood coagulation by shaking the tube with hand or stirer machine.
  • Nan Tze District, Kaohsiung City lastly, Stops bleeding in tonsillectomy rat within one second by topical use of this (f). Claims of Utilities of ascorbic acid powder.
  • this powder topically in to her bleeding nostril.

Abstract

A method for stopping bleeding is described. The method entails applying to the site of bleeding powdered Vitamin C.

Description

SUBSTANCE THAT CAN STOP BLEEDING IN SURGICAL, MEDICAL AND DENTAL
USES/SUBSTANCE POWDER 001 THAT CAN STOP BLEEDING DURING SURGERY,
AFTER SURGERY, MEDECINE, DENTISTRY OR ANY BLEEDING DUE TO ANY CAUSES
SPECIFICATION OF INVENTION
(a) Title of the Invention.
The substance powder 001 that can stop (stanch) bleeding in surgical, postsurgical, medical and dental uses or any bleeding due to any causes by topical administration or the substance powder 001 that has very potent hemostatic action can be administered topically to stop bleeding during surgery, after surgery, medicine by ingestion, dental surgery, extraction of teeth, and any injury or due to any causes for any normal and pathological persons.
(b) Cross-References to Related Applications.
The early literature on scurvy due to vitamin C deficiency was reviewed by Bourne in 1944, he showed hieroglyphs from Egyptian papyri as convincing evidence that this disease, charaterized by bleeding gums and hemorrhages in the skin, existed about 3000 years ago. A sudden pain seized their feet, and legs;
immediately afterwards the gums and teeth were attacked by a sort of gangrene. The bones of the legs become horribly black. The legs shrivelled up and became covered with black spots. It was a sure sign of death when the nose began to bleed. ( Bourne, G,H, 1944, Proc. R. Soc. Med., 37, 512 ) PATNAIK 1971 stated that the concentration of ascorbio acid has been reported as decreasingwith age in the rat eye lens, adrenal, brain, testis, and blood. ( Patnaik, B.K. 1971,
Gerontologia, 17, 122 ) Purpura (extensive bruising ) and hemorrhages under the tongue are common in elderly people.
Tattersal and Seville 1950 reported purpura in 60 out of 809 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and forearms. and on the backs of their hands, noth patients. and the controls were ascorbate deficient, as judged by ascorbic acid loading tests; skin biopsies from those with purpura showed degeneration of the collagen fibres of the dermis. Tattersall (c) Background of the Invention.
(1) THIS invention pertains to the field of disorder of hemostasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboembolic disorders. However, the blood coagulation mechanism of ascorbi c acid which was administered topically does not fall into either
intrinsic or extrinsic pathway cascade, since it works the same for hemostasis in normal situation as in chronic- hepatitis, colon cancer, and hemophilia patients in
whom the coagulation factors 2, 7, 9, 10 in the l iver disease and factor 8 or 9 in the hemophilia A or B cannot be produced. (2) The present methods available to stop bleeding in surgery are cautery, epinephrine injection, pressure and some fiber foam. The cautery can cause tissue necrosis in
some cases. The epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly w el l for diffuse capillary bleeding and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency of the kinds of aforementioned patients. The ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRNA in the regulation of col l agen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
Substance powder 001 represents ascorbic acid powder that is obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding when spraying it topically on the bleeding a rea for any
normal or any diseased pa t ient s . When t he powder come s i n contact with the blood, the black tar gel like material is formed, and later becomes solid. The amount of the powder that is
needed to react completely with the blood is proportional
to the amount of the blood that comes out of the blood
vessels. In rats, one capillary, one venous and one femoral artery bleeding were stanched within one second, if sufficient amounts of the powder of ascorbic acid were applied. The artery bleeding needs much more this powder of interest. In the test tube conditions, it requires 0.1568 g of this substance powder to coagulate ( make the blood black and not move in the tube ) 1 ml of human blood in 6 minutes. This is the same for normal, colon cancer and hemophilia patients; 1 ml of normal blood
needs 0.1568 g of ascorbic acid powder, 1 ml of colon cancer blood needs 0.1568 g of ascorbic acid powder, and 1 ml of
hemophilia blood needs 0.1568 g of ascorbic acid powder. Sufficient substance powder 001 is particularly useful to help stop bleeding in the case of diffuse capillary oozing and mistakenly cut off artery or arteries that cannot be found during massive bleeding bleeding so as to save the patients' lives.
The present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, pressure and some fiber foam. The cautery can cause tissue necrosis in some cases. The epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capi l l ary oozing patients, while ascorbic acid powder does not cause any tissue necrosis and particularly works well for diffuse capillary bleeding and oozing and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients. The ascorbic acid also facilitate wound healing ( Oral Surg. 1982 Mar: 53 (3): 231-6 ) by increasing type 1 procollagen mRNA in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) and when the vitamin C is absorbed into the system, it is good for health by making the leucocytes stronger and slowing the aging process etc, ( Patnaik and Kanungo 1964, Gerontologia, 10, 155 ) as long as it is within the optimal dose such as 1 g, However, at the end of operation before closure, the excessive black tar gel like material can be wiped away
and washed with Ringer's solution.
( e) Description of the preferred embodiments of the invention:
As already mentioned previously, the substance powder 001 is made by grinding the pure vitamin C tablets into powder.
Application of this powder topically to the bleeding area is better by spraying the powder topically on the bleeding area.
The amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this vitamin C powder to coagulate 1 ml of human blood. This is the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this situation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows:
(f) Rats Experiments
1) Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off. ( Photograph # 1 : massive bleeding when the femoral artery is cut off ) ( Photogrph # 2: bleeding stops within one second when sufficient powder of interest was poured topically into
the bleeding area, in this case of massive active bleeding I did pouring instead of spraying. The amount of the powder needed is proportional to the amount of blood coming out of the vessel.
It varies with the rats. Usually 0.1344 g is sufficient to stop bleeding for the femoral artery of the rat which is cut off within one second. In the photograph # 2, the black tar gel like material was formed in one second as soon as the powder contacts with the blood . Those white spots indicate the powder that is not yet mixed up with the blood. The black gel forms first on the surface of the pond of blood, that stop the fluid moving. If stirring the blood to break through the surface film like structure that keep the blood fluid from moving when the powder is insufficien it will bleed again, but slower than ( much slower ) before
pouring the powder into the bleeding area; but after adding
sufficient powder into the blood, stirring makes the powder
molecules well saturated with the hemoglobin and plasma proteins molecules and thus forming the concentrated black sticky gel like structure. After 5-6 minutes, when most of the sticky tar like structure is wiped away, it appears there is no bleeding at
all. ( Photograph # 3 ). In the case of capillary bleeding
in which one capillary is cut off, about 0. 0112 g of this
powder can stop the bleeding within one second, ( Photograph #
4 ). After 1 minute count from adding the powder, it appears there is no more bleeding while wiping away the black tar gel like structure, while in the case of one vein cut of f , i t needs abou t 0.0224 g of the powder to stop bleed i ng , and about after 1 1/2 minutes, it appears there is no more bleeding when the black coagulation is wiped away. ( Photograph # 5 ).
The nostril was cut slightly to bleed ( Photograph # 6 ) in rat, the bleeding stop within one second when applying this powder
0.0037 g topically into the bleeding nostril, ( Photograph #
7 ). After injection of histamin into the rat, it induces
secretion of gastric acid, open up the stomach ( Photograph #
8 ), cut the mucosa layer to bleed ( Photograph # 9 ), applying the powder topically to the bleeding area, the black coagulation formed, but slower than normal, since the secretion dilute the black coagulation. ( Photograph # 10) Thus this powder can
treat the gastric ulcer bleeding when it is ingested orally. Clinical Evidence.
This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
Case 1. Age 32, male, scalp tumor excision, massive bleeding
when the tumor vas excised. ( Photograph # 11 ) Sufficiently spraying this powder into the bleeding area also help stop bleeding before it was closed by suture. ( Photograph # 12 )
Case 2. Age 40, female, acute renal failure, A-V fistula formation operation, massive bleeding ( Photograph * 13 )
The operation of stopping bleeding consists of combining the powder with press with gauze. When applying this powder to the bleeding area, those that look black in color indicate the black blood coagulation ( Photograph # 14), while those that are white in color are those the powder does not get mixed up with the blood ( Photograph # 15). At the end of the operation, most of black blood coagulation was wiped out with 4x4 gauze, and rinsed with Ringer's solution ( Photograph # 16 ). It took totally 5 minutes to stop the bleeding completely. The patient's conditions are especially well, better than without using this powder.
Case 3. Age 40, male, skin contracture on the palm, which needs
to be removed, and it requires skin graft.
When the skin graft is removed from the hand,massive bleeding occurs ( Photograph # 17) . On applying sufficient powder to the bleeding area topically, it appears black coagulation within one second. Bleeding stops nt the same time ac the black coagulation forms. Those that appears white indicate the powder not yet mixed up with the blood. ( Photograph 4 18); those that appears more black area indicate the more powder mixed up with the blood (Photograph # 19), Suture going on ( Photograph # 20 ) Case 4. Age 70, female, paraanal abscess excision, bleeding when it is opened up ( Photograph # 21 ). When spraying the powder to the bleeding area, it stop bleeding by forming black blood coagulation immediately. Those that appears white are the powder that are not mixed up with the blood. ( Photograph # 212), Suture going on ( Photograph # 23 ).
Case 5. Age 50, male, paraanal abscess excision.
maasive bleeding when it is opened up ( Photograph # 24 ). On spraying the powder topically to the bleeding area, the black color is formed immediately because of the blood coagulation ( Photograph # 25 ) . The white color is the powder instantly not mixed up with the blood yet. ( Photograph # 25 ), lastly, insert the long gauze into the anus. ( Photograph # 27 )
Case 6. Age 30, male, extraction of tooth, the gum injected bleeds
( Photograph # 28 ). Applying this powder topically to the bleeding area, the bleeding stop within one second and black blood coagulation forms within one second
( Photograph # 29 ) . Wipe out the black coagulation in 10 seconds, stop bleeding still persisted ( Photograph # 30 )
Case 7. Age 60, female, chronic hepatitis, has bleeding tendency, extraction of teeth cause massive bleeding ( Photograph # 31 ) On applying this powder to the socket of the gum, the black coagulation forms within one second, the bleeding of Ihis socket stops within one second accordingly.
( Photograph # 32 )
Case 8. myself, finger little scratched, slightly bleeds
( Photograph # 33 ). Upon contact with the powder, the black color forms within one second or shorter ( Photo In test, tube condition as mentioned previously, 1 ml of human
blood requires 0.1568 g of powder to form black blood coagulation by shaking the tube with hand or stirer machine.
It takes 6 minutes to form the unmobile black coagulation
in the test tube for normal, liver diseases, colon cancer
and hemophilia blood respectively. ( Photograph # 35 normal
blood, colon cancer Photograph # 36, and hemophilia blood
Photograph # 37 ) This indicates that the mechanism of
the coagulation by this powder does not involve the coagulation
factors. The hemophilia blood ( both prior to adding the powder
and after adding powder) are still stored in the freezer here.
This patient's name: Su Jean Wang, Age 25, male, D.I.
# S 121745233, address: No 5, Su Ming Rd., Lane 100
Nan Tze District, Kaohsiung City , lastly, Stops bleeding in tonsillectomy rat within one second by topical use of this (f). Claims of Utilities of ascorbic acid powder.
1. Stops bleeding in the nose bleeding in humans w i thin one
second, experienced in my 6 years old daughter by applying
this powder topically in to her bleeding nostril.
2 . Stops bleeding in any ijury due to any cause, this also be
useful for wound bleeding in the war or combat zone.
3. Stops bleeding in bleeding tendency patients in surgery
or after surgery. Help stop bleeding in A-V fistula formation
surgery in preparation for hemodialysis.
4. Stops bleeding in massive bleeding in scalp tumor excision.
5. Stops bleeding in bleeding tendency in paranal abscess
oxcision.
6. Stops bleeding in postoperation ( after surgery ) bleeding
in perineum wound bleeding after rectal anal cancer surgery.
7. Stops bleeding in teeth extraction within one second in
bleeding tendency patients when applying this powder topically
to the bleeding socket of the gum.
8. Stops bleeding in the hemophilia patients due to injury when
applying the powder topically to bleeding area sufficiently.
9. Stops bleeding in Ob & Gyn surgery in bleeding tendency

Claims

patients when applying this powder sufficiently to the
bleeding area.
10. Stops bleeding due to injury or bleeding due to any causes.
11. Stops gastric ulcer bleeding when ingestion of this powder about 1 g / day orally.
12. Help stop and prevent internal bleeding when taking
1 g of this powder daily orally.
13. Stops bleeding and help stop bleeding in tonsillectomy
and
and after tonsillectomy bleeding. 14. The ascorbic acid powder is
obtained by grinding the
v itami n C tablets into powder
PCT/US1991/009201 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes WO1992010999A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU91034/91A AU662505B2 (en) 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes
EP92901379A EP0644754A4 (en) 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes.
NO1993930858A NO930858D0 (en) 1990-12-06 1993-03-09 SUBSTANCE THAT CAN STOP BLEEDING, eg. BY SURGICAL AND DENTAL INTERVENTIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62409490A 1990-12-06 1990-12-06
US624,094 1990-12-06

Publications (1)

Publication Number Publication Date
WO1992010999A1 true WO1992010999A1 (en) 1992-07-09

Family

ID=24500629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/009201 WO1992010999A1 (en) 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes

Country Status (5)

Country Link
EP (1) EP0644754A4 (en)
AU (1) AU662505B2 (en)
CA (1) CA2095439C (en)
NO (1) NO930858D0 (en)
WO (1) WO1992010999A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755592A (en) * 1971-02-19 1973-08-28 G Ahrens Method of preparing high concentration calcium ascorbate reaction products and products produced by same
US4959362A (en) * 1983-12-19 1990-09-25 Takeda Chemical Industries, Inc. Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336925A1 (en) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc.
JPS6029361B2 (en) * 1977-03-04 1985-07-10 白井松新薬株式会社 Pharmaceutical composition with enhanced hemostatic effect
NO161779C (en) * 1986-04-22 1989-10-04 Olav Johan Braenden PROCEDURE FOR PREPARING AN ANTI-COOLING PREPARATION.
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755592A (en) * 1971-02-19 1973-08-28 G Ahrens Method of preparing high concentration calcium ascorbate reaction products and products produced by same
US4959362A (en) * 1983-12-19 1990-09-25 Takeda Chemical Industries, Inc. Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0644754A4 *

Also Published As

Publication number Publication date
AU662505B2 (en) 1995-09-07
EP0644754A1 (en) 1995-03-29
NO930858D0 (en) 1993-03-09
CA2095439A1 (en) 1992-06-07
CA2095439C (en) 1998-12-08
EP0644754A4 (en) 1995-12-27
AU9103491A (en) 1992-07-22

Similar Documents

Publication Publication Date Title
SE443510B (en) SET TO MAKE AGENTS FOR IMPROVING BREATHING AND COLLECTION, INCLUDING EXTRACTS OF BLOOD EXEMPT FROM EGGVITA
JPS6069028A (en) Drug composition containing insulin
Maxwell et al. Vascular complications of drug abuse
JPH04149126A (en) Pharmaceutical composition for transmucous administration
FR2491475A1 (en) PROCESS FOR THE PREPARATION OF CHONDROITI SULFATE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US5639482A (en) Composition for control and prevention of diabetic retinopathy
AU662505B2 (en) Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes
CN104784193B (en) Pharmaceutical application of protopanaxadiol type notoginsenoside
Collens et al. The use of intermittent venous compression in the treatment of peripheral vascular disease: A preliminary report
Burch et al. Lower nephron syndrome
US6783774B1 (en) Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses
Witkind et al. APLASIA OF THE BONE MARROW DURING MESANTOIN® THERAPY: REPORT OF A FATAL CASE
Vaughan et al. Skin necrosis of genitalia and warfarin therapy
JP2009191015A (en) Wound healing promoter
Collings et al. Three cases of inoculation of tuberculosis from tattooing
Gershon-Cohen et al. The effect of osmotic changes in the small intestine upon gastric emptying in man
Schmier Fascial hernia of both lower extremities: Injection with sodium morrhuate
Walsham Surgery: its theory and practice
Chandler et al. Benign duodeno-colonic fistula
CN106806378B (en) The pharmaceutical applications of notoginsenoside Fc
Clements Manifestations of nutritional deficiency in infants
Krishna Study of Surgincal Complicatons in Diabetic Patients Among The Rural Population
Pederson Physiology and treatment of severe burns: with special reference to burn shock
RU2228194C2 (en) Means for preventing from hemorrhagic blood-coagulating and edematous necrotic activity of snake venom
Smith Laparoscopic cholecystectomy.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2095439

Country of ref document: CA

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 1992901379

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992901379

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992901379

Country of ref document: EP